Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma. Issue 1 (2nd January 2020)

• Record Type: Journal Article
• Authors: Lopez, James; Yarlagadda, Naveen; Gheith, Zaid; Mohan, Meera; Sasapu, Appalanaidu
• Is Part Of: Proceedings. Volume 33:Issue 1(2020)
• Page Start: 59
• Page End: 61
• Publication Date: 2020-01-02
• Subjects: Hodgkin lymphoma -- immune-mediated adverse reaction -- neurotoxicity -- nivolumab; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2019.1668719
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: Nivolumab, a monoclonal antibody against programmed cell death-1 used to treat multiple cancers, has fewer side effects than traditional chemotherapy but has displayed a propensity to cause a host of immune-related adverse events. We describe a case of nivolumab immune-mediated neurotoxicity in a 42-year-old Hispanic man with relapsed Hodgkin lymphoma who presented with unilateral facial droop, dysarthria, and dysphagia 1 week after receiving nivolumab. His symptoms rapidly improved with steroids, intravenous immunoglobulin, and infliximab.